贝伐单抗联合化疗治疗肺癌的研究新进展

被引：13

作者：

刘贤忠 ^{[1
]}

张丽婷 ^{[1
]}

陈芳 ^{[2
]}

机构：

[1] 浙江中医药大学第一临床医学院

[2] 浙江中医药大学附属第一医院肺功能室

来源：

实用肿瘤杂志 | 2015年 / 30卷 / 04期

关键词：

肺肿瘤/治疗; 抗体,单克隆/治疗应用; 抗肿瘤联合化疗方案/治疗应用; 综述;

D O I：

10.13267/j.cnki.syzlzz.2015.04.024

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

肺癌是最常见的恶性肿瘤之一,其发病率和死亡率在逐年升高。自从靶向药物贝伐单抗被批准用于治疗肺癌后,关于贝伐单抗治疗肺癌的研究即进入大量的临床试验。贝伐单抗在治疗肺癌时显示出一定的优势,其联合化疗时疗效较为显著且安全。现将近年来贝伐单抗联合化疗在肺癌中的研究进展作一综述。

引用

页码：385 / 389

页数：5

共 15 条

[1]

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease [J].

Shimizu, Ryoko ;

Fujimoto, Daichi ;

Kato, Ryoji ;

Otoshi, Takehiro ;

Kawamura, Takahisa ;

Tamai, Koji ;

Matsumoto, Takeshi ;

Nagata, Kazuma ;

Otsuka, Kyoko ;

Nakagawa, Atsushi ;

Otsuka, Kojiro ;

Katakami, Nobuyuki ;

Tomii, Keisuke .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) :1159-1166

[2]

Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study [J].

Wozniak, A. J. ;

Kosty, M. P. ;

Jahanzeb, M. ;

Brahmer, J. R. ;

Spigel, D. R. ;

Leon, L. ;

Fish, S. ;

Flick, E. D. ;

Hazard, S. J. ;

Lynch, T. J., Jr. .

CLINICAL ONCOLOGY, 2015, 27 (04) :187-196

[3]

Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.[J].C. Zhou;Y. Wu;G. Chen;X. Liu;Y. Zhu;S. Lu;J. Feng;J. He;B. Han;J. Wang;G. Jiang;C. Hu;H. Zhang;G. Cheng;X. Song;Y. Lu;H. Pan;W. Zheng;A. Yin.International Journal of Radiation Oncology; Biology; Physics.2014, 5S

[4]

Cost Effectiveness of Nab-Paclitaxel Plus Carboplatin (nab-PC) Relative to Bevacizumab Plus Solvent-Based Paclitaxel and Carboplatin (B+sb-PC) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).[J].V. Hirsh;A. Berger;G. Binder;C. Langer;T.J. Ong;M. Renschler;R. Bornheimer;S. Whiting;G. Oster.International Journal of Radiation Oncology; Biology; Physics.2014, 5S

[5]

Phase II study of pemetrexed and carboplatin plus bevacizumab; followedby maintenance pemetrexed and bevacizumab in Japanese patients with non‑squamousnon‑small cell lung cancer.[J].Takashi Yokoi;Yoshitaro Torii;Yuichi Katashiba;Hiroyuki Sugimoto;Tsutomu Tanijiri;Makoto Ogata;Noriko Inagaki;Kayoko Kibata;Mina Hayashi;Maiko Niki;Toshiki Shimizu;Takayuki Miyara;Takayasu Kurata;Shosaku Nomura.Oncology Letters.2014, 6

[6]

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC) [J].